Operating Lease, Right-of-Use Asset of CytomX Therapeutics, Inc. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
CytomX Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • CytomX Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $4,814,000, a 48% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

CytomX Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $4,814,000 -$4,379,000 -48% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $5,947,000 -$4,278,000 -42% 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $7,055,000 -$4,179,000 -37% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $8,136,000 -$4,084,000 -33% 31 Dec 2024 10-Q 06 Nov 2025 2025 Q3
Q3 2024 $9,193,000 -$3,991,000 -30% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $10,225,000 -$3,901,000 -28% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $11,234,000 -$3,814,000 -25% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $12,220,000 -$3,729,000 -23% 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $13,184,000 -$3,646,000 -22% 30 Sep 2023 10-Q 07 Nov 2023 2023 Q3
Q2 2023 $14,126,000 -$3,566,000 -20% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $15,048,000 -$3,488,000 -19% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $15,949,000 -$3,413,000 -18% 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q3 2022 $16,830,000 -$3,340,000 -17% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $17,692,000 -$3,269,000 -16% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $18,536,000 -$3,200,000 -15% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $19,362,000 -$3,133,000 -14% 31 Dec 2021 10-K 27 Mar 2023 2022 FY
Q3 2021 $20,170,000 -$3,069,000 -13% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $20,961,000 -$3,006,000 -13% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $21,736,000 -$2,946,000 -12% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $22,495,000 -$2,887,000 -11% 31 Dec 2020 10-K/A 27 Mar 2023 2021 FY
Q3 2020 $23,239,000 -$2,830,000 -11% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $23,967,000 -$2,776,000 -10% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $24,682,000 -$700,000 -2.8% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $25,382,000 31 Dec 2019 10-K 24 Feb 2021 2020 FY
Q3 2019 $26,069,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $26,743,000 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $25,382,000 31 Mar 2019 10-Q 07 May 2020 2020 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.